Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) rose 4.7% during mid-day trading on Tuesday . The stock traded as high as $28.65 and last traded at $28.40. Approximately 173,823 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 446,608 shares. The stock had previously closed at $27.13.
Wall Street Analyst Weigh In
ARCT has been the subject of a number of recent research reports. Guggenheim restated a “buy” rating on shares of Arcturus Therapeutics in a research note on Friday, July 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $54.00 target price on shares of Arcturus Therapeutics in a research report on Tuesday, August 22nd. StockNews.com began coverage on Arcturus Therapeutics in a report on Thursday, August 17th. They set a “hold” rating on the stock. Wells Fargo & Company increased their price objective on Arcturus Therapeutics from $35.00 to $45.00 in a report on Monday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $51.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, September 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Arcturus Therapeutics has an average rating of “Hold” and a consensus price target of $38.78.
Arcturus Therapeutics Stock Performance
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last released its earnings results on Monday, August 7th. The biotechnology company reported ($1.98) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($2.07). The business had revenue of $10.52 million during the quarter, compared to the consensus estimate of $71.05 million. Arcturus Therapeutics had a return on equity of 20.75% and a net margin of 30.36%. As a group, equities research analysts predict that Arcturus Therapeutics Holdings Inc. will post -3.56 earnings per share for the current year.
In other news, COO Pad Chivukula sold 5,000 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $28.75, for a total transaction of $143,750.00. Following the sale, the chief operating officer now directly owns 544,448 shares of the company’s stock, valued at $15,652,880. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Arcturus Therapeutics news, insider Keith C. Kummerfeld sold 6,968 shares of Arcturus Therapeutics stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $35.00, for a total transaction of $243,880.00. Following the transaction, the insider now directly owns 950 shares in the company, valued at approximately $33,250. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Pad Chivukula sold 5,000 shares of Arcturus Therapeutics stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $28.75, for a total value of $143,750.00. Following the transaction, the chief operating officer now owns 544,448 shares in the company, valued at approximately $15,652,880. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,968 shares of company stock worth $1,420,130. Insiders own 13.80% of the company’s stock.
Institutional Investors Weigh In On Arcturus Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Bank Julius Baer & Co. Ltd Zurich increased its stake in Arcturus Therapeutics by 85,285.3% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 59,829,489 shares of the biotechnology company’s stock valued at $1,715,910,000 after buying an additional 59,759,419 shares during the period. State Street Corp lifted its stake in shares of Arcturus Therapeutics by 56.5% in the 1st quarter. State Street Corp now owns 3,217,957 shares of the biotechnology company’s stock valued at $86,756,000 after purchasing an additional 1,161,883 shares during the last quarter. Bank of America Corp DE boosted its holdings in Arcturus Therapeutics by 535.2% in the fourth quarter. Bank of America Corp DE now owns 685,954 shares of the biotechnology company’s stock worth $11,634,000 after purchasing an additional 577,968 shares in the last quarter. Federated Hermes Inc. increased its position in Arcturus Therapeutics by 12.7% during the first quarter. Federated Hermes Inc. now owns 4,778,500 shares of the biotechnology company’s stock worth $114,541,000 after buying an additional 538,946 shares during the last quarter. Finally, Balyasny Asset Management LLC increased its position in Arcturus Therapeutics by 3,039.8% during the third quarter. Balyasny Asset Management LLC now owns 339,383 shares of the biotechnology company’s stock worth $5,030,000 after buying an additional 328,574 shares during the last quarter. 88.87% of the stock is currently owned by institutional investors and hedge funds.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
- Five stocks we like better than Arcturus Therapeutics
- Business Services Stocks Investing
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Invest in Social Media
- Virtual Riches: 3 Stocks Leading the VR Revolution
- How to Start Investing in Penny Stocks
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.